Literature DB >> 27056371

The liver in focus.

Michael Roden1,2,3.   

Abstract

Keywords:  GLP-1 agonists; Hepatokines; Insulin resistance; Lipogenesis; Liver; Mitochondria; Non-alcoholic fatty liver disease; Thiazolidendiones

Mesh：

Year:  2016        PMID： 27056371     DOI： 10.1007/s00125-016-3911-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.

Authors:  Rachel J Perry; Dongyan Zhang; Xian-Man Zhang; James L Boyer; Gerald I Shulman
Journal:  Science       Date:  2015-02-26       Impact factor: 47.728

Review 2.  Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

Authors:  Siddharth Singh; Rohan Khera; Alina M Allen; M Hassan Murad; Rohit Loomba
Journal:  Hepatology       Date:  2015-10-01       Impact factor: 17.425

3.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

4.  Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis.

Authors:  Chrysi Koliaki; Julia Szendroedi; Kirti Kaul; Tomas Jelenik; Peter Nowotny; Frank Jankowiak; Christian Herder; Maren Carstensen; Markus Krausch; Wolfram Trudo Knoefel; Matthias Schlensak; Michael Roden
Journal:  Cell Metab       Date:  2015-05-05       Impact factor: 27.287

Review 5.  Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease.

Authors:  Chrysi Koliaki; Michael Roden
Journal:  Mol Cell Endocrinol       Date:  2013-06-12       Impact factor: 4.102

Review 6.  Diagnosis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Hannele Yki-Järvinen
Journal:  Diabetologia       Date:  2016-04-18       Impact factor: 10.122

7.  Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle.

Authors:  Christian Anderwald; Elisabeth Bernroider; Martin Krssak; Harald Stingl; Attila Brehm; Martin G Bischof; Peter Nowotny; Michael Roden; Werner Waldhäusl
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

8.  Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo.

Authors:  Paul M Titchenell; Qingwei Chu; Bobby R Monks; Morris J Birnbaum
Journal:  Nat Commun       Date:  2015-05-12       Impact factor: 14.919

Review 9.  Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.

Authors:  Kenneth Cusi
Journal:  Diabetologia       Date:  2016-04-21       Impact factor: 10.122

10.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Authors:  Matthew James Armstrong; Piers Gaunt; Guruprasad P Aithal; Darren Barton; Diana Hull; Richard Parker; Jonathan M Hazlehurst; Kathy Guo; George Abouda; Mark A Aldersley; Deborah Stocken; Stephen C Gough; Jeremy W Tomlinson; Rachel M Brown; Stefan G Hübscher; Philip N Newsome
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321
  10 in total
  1 in total

1.  Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.

Authors:  Andras Franko; Susanne Neschen; Jan Rozman; Birgit Rathkolb; Michaela Aichler; Annette Feuchtinger; Laura Brachthäuser; Frauke Neff; Marketa Kovarova; Eckhard Wolf; Helmut Fuchs; Hans-Ulrich Häring; Andreas Peter; Martin Hrabě de Angelis
Journal:  Mol Metab       Date:  2017-01-06       Impact factor: 7.422
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.